'Reassuring Data' for Two Multiple Sclerosis Meds in Pregnancy
Two studies report few complications from continuing ocrelizumab and natalizumab into pregnancy, with high live birth rates, a decline in elective abortions, and few major congenital abnormalities in newborns.
Source: medscape.com